Processa Pharmaceuticals ...
0.85
0.02 (2.53%)
At close: Jan 15, 2025, 12:52 PM
undefined%
Bid 0.83
Market Cap 3.13M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -4.8
PE Ratio (ttm) -0.18
Forward PE n/a
Analyst Buy
Ask 0.87
Volume 7,798
Avg. Volume (20D) 337,059
Open 0.83
Previous Close 0.83
Day's Range 0.83 - 0.87
52-Week Range 0.80 - 7.14
Beta undefined

About PCSA

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selectiv...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 7, 2014
Employees 13
Stock Exchange NASDAQ
Ticker Symbol PCSA

Analyst Forecast

According to 2 analyst ratings, the average rating for PCSA stock is "Buy." The 12-month stock price forecast is $5, which is an increase of 490.04% from the latest price.

Buy 50.00%
Hold 0.00%
Sell 0.00%
Stock Forecasts
3 months ago · Source
+0%
Processa Pharmaceuticals shares are trading higher... Unlock content with Pro Subscription
5 months ago · Source
+34.12%
Processa Pharmaceuticals shares are trading higher after the company announced FDA clearance of its IND application for a Phase 2 clinical trial of NGC-Cap in breast cancer.